Evidence for cPLA2 activation in Alzheimer's Disease Synaptic Pathology

Area of Science:

• Neuroscience
• Biochemistry
• Pathology

Background:

• Synaptic loss is a hallmark of Alzheimer's disease (AD), correlating with cognitive decline.
• The precise molecular mechanisms driving AD-related synaptic loss remain unclear.
• Calcium-dependent phospholipase A2 (cPLA2) releases arachidonic acid, a precursor to inflammatory eicosanoids, suggesting its potential role in AD pathology.

Purpose of the Study:

• To investigate the role of cPLA2 in synaptic loss and cognitive dysfunction in Alzheimer's disease.
• To examine cPLA2 levels and activity in human brain tissue and iPSC-derived neurons exposed to amyloid-beta.

Main Methods:

• Analysis of cPLA2 levels in synaptosomes from individuals with varying cognitive impairment.
• Lipidomic analysis of eicosanoids and immunofluorescent staining for cPLA2 and synaptic markers.
• In vitro studies using human iPSC-derived neurons exposed to amyloid-beta oligomers (Aβ42O) and cPLA2 inhibitors.

Main Results:

• Elevated cPLA2 (cPLA2α and cPLA2β) and eicosanoids were found in AD synaptosomes, correlating with cognitive decline.
• Phosphorylated cPLA2α (p-cPLA2α) colocalized with synaptic proteins (PSD-95, CaMKIIα, MAP2) in AD brains and Aβ42O-exposed neurons.
• Aβ42O-induced cPLA2α activation led to synaptic marker reduction, an effect reversed by a cPLA2 inhibitor.

Conclusions:

• cPLA2 overactivation in synapses, dendrites, and neuronal somas is linked to synaptic loss, neurodegeneration, and cognitive decline in AD.
• cPLA2 represents a potential therapeutic target for modifying Alzheimer's disease progression.
• Further research is warranted to explore cPLA2 as a disease-modifying target for AD.